GlassScriptPhysician profile
Lainey D Briggs
NPI 1083039788
$17,451.43
in general payments reported to CMS, 2019-2025
68 companies · $4,102 in 2025
The $4,102 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,884 · 2022: $3,357 · 2023: $3,905 · 2024: $3,204 · 2025: $4,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,629.57 |
| Education | $580.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,241.70 | 2021-2025 | Opdivo, Opdualag, Breyanzi |
| Janssen Biotech, INC. | $1,118.91 | 2021-2025 | Tecvayli, Darzalex, Erleada |
| Astrazeneca Pharmaceuticals LP | $1,064.65 | 2021-2025 | Calquence, Tagrisso, Enhertu |
| Celgene Corporation | $928.35 | 2021-2025 | Reblozyl, Pomalyst, Breyanzi |
| Merck Sharp & Dohme LLC | $796.14 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Genentech USA, INC. | $776.31 | 2021-2025 | Phesgo, Perjeta, Polivy |
| Pfizer INC. | $747.20 | 2021-2025 | |
| Amgen INC. | $744.46 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Genzyme Corporation | $639.72 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $637.69 | 2022-2025 | |
| Abbvie INC. | $554.06 | 2021-2025 | |
| Incyte Corporation | $552.97 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Lilly USA, LLC | $542.48 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $489.53 | 2021-2023 | Tukysa, Adcetris |
| Eisai INC. | $460.10 | 2021-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $447.19 | 2021-2025 | Fotivda |
| Glaxosmithkline, LLC. | $426.77 | 2021-2025 | Jemperli, Ojjaara |
| Astellas Pharma US INC | $360.79 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Gilead Sciences, INC. | $348.64 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $343.41 | 2021-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $331.37 | 2021-2025 | Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $316.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $261.39 | 2021-2025 | Libtayo, Lynozyfic |
| Mirati Therapeutics, INC. | $211.77 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $211.26 | 2021-2023 | Imbruvica, Epkinly |
| Alexion Pharmaceuticals, INC. | $192.90 | 2021-2025 | Ultomiris |
| Emd Serono, INC. | $191.20 | 2021-2025 | |
| Kite Pharma, INC. | $187.91 | 2023-2025 | Yescarta |
| Puma Biotechnology, INC. | $176.58 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $172.21 | 2021-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $170.34 | 2021-2025 | Qinlock, Romvimza |
| Exelixis INC. | $141.08 | 2021-2025 | Cabometyx |
| Genmab U.S., INC. | $109.81 | 2023-2025 | Epkinly |
| Blueprint Medicines Corporation | $85.56 | 2022-2024 | Ayvakit |
| Array Biopharma INC | $84.56 | 2023-2025 | Xalkori, Braftovi, Mektovi |
| Taiho Oncology, INC. | $84.44 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2025 | |
| Kyowa Kirin, INC. | $73.79 | 2023-2024 | Poteligeo |
| Sobi, INC | $72.32 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $69.78 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $69.73 | 2022 | |
| Myovant Sciences INC. | $67.36 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $66.76 | 2022-2025 | Onivyde |
| Epizyme, INC. | $60.88 | 2021 | |
| Novocure INC. | $58.87 | 2025 | Optune Lua (Novottf-200t) |
| Pharmacosmos Therapeutics INC. | $56.19 | 2021-2025 | Cosela, Monoferric |
| Adc Therapeutics America, INC. | $55.62 | 2022-2025 | |
| Acceleron Pharma, INC. | $50.76 | 2021 | |
| Tersera Therapeutics LLC | $49.44 | 2021-2024 | Zoladex |
| Clovis Oncology, INC. | $46.78 | 2021 | |
| Myriad Genetic Laboratories, INC. | $43.59 | 2021-2024 | Precisetumor |
| Servier Pharmaceuticals LLC | $38.40 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.15 | 2024 | Gilotrif |
| Beigene USA, INC. | $35.25 | 2024-2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $26.37 | 2025 | |
| Legend Biotech USA INC. | $23.92 | 2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $23.46 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $22.96 | 2023 | Besremi |
| Caris Mpi, INC. | $21.07 | 2025 | Mi Cancer Seek |
| Verity Pharmaceuticals INC. | $19.07 | 2023 | Trelstar |
| Acrotech Biopharma INC. | $18.71 | 2023 | Beleodaq |
| Geron Corporation | $18.01 | 2024 | Rytelo |
| Morphosys, US INC. | $17.90 | 2023 | Monjuvi |
| Adaptive Biotechnologies Corporation | $17.85 | 2023 | Clonoseq |
| Beone Medicines USA, INC. | $17.68 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $13.14 | 2022 | |
| Dova Pharmaceuticals | $13.07 | 2021 | |
| Secura Bio, INC. | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lainey Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.